EoE Module 10 References-AGA Abstracts 538 Hara et al DDW 2021

AGA Abstracts 538 Hara et al DDW 2021

Pdf Summary

The document provides summaries of three studies focused on treatment approaches for eosinophilic conditions, particularly eosinophilic esophagitis (EoE) and related disorders.<br /><br />1. **Omeprazole Treatment in EoE**: The first study investigates how omeprazole, a proton pump inhibitor, can restore CD73 basal progenitor cells, which are depleted in the inflammatory milieu of eosinophilic esophagitis. EoE, characterized by basal cell hyperplasia (BCH), relies on the renewal of esophageal epithelium via CD73-expressing cells. The study demonstrated that omeprazole, along with a STAT6 inhibitor, mitigates the impact of Th2 cytokines (IL-4 and IL-13) associated with EoE, thereby potentially offering a therapeutic strategy to maintain epithelial homeostasis and manage EoE effectively.<br /><br />2. **Lirentelimab for Eosinophilic Gastritis and Duodenitis**: The second report covers the extended results of a study on lirentelimab, a monoclonal antibody against siglec-8, targeted at eosinophilic gastritis and duodenitis. Lirentelimab showed promising results in significantly depleting eosinophils and relieving GI symptoms over 70 weeks. The long-term treatment improved patient-reported gastrointestinal symptom scores and achieved histological remission in a substantial number of patients, suggesting lirentelimab as a viable treatment option for long-term management of eosinophilic gastrointestinal disorders.<br /><br />3. **Fluticasone Treatment for EoE**: The FLUTE trial assessed APT-1011, an orally disintegrating tablet of fluticasone propionate, to treat EoE. It particularly noted improvements in patients with fibro-stenotic features like strictures and rings. Compared to placebo, APT-1011 significantly enhanced histologic, endoscopic, and symptomatic outcomes by reducing eosinophil counts and endoscopic signs, affirming its efficacy even among patients with structural esophageal afflictions.<br /><br />Overall, these studies underscore progress in managing eosinophilic gastroenterological conditions through targeted therapies, which enhance patient quality of life by addressing underlying pathophysiological pathways.

Keywords

eosinophilic esophagitis

omeprazole

lirentelimab

fluticasone

eosinophilic gastritis

eosinophilic duodenitis

CD73 basal progenitor cells

Th2 cytokines

siglec-8

APT-1011